IRCT20150101020514N21尚未招募2 期
Evaluating the safety (safety/harmlessness) and effectiveness of Sigol brand insect repellent spray in healthy volunteer
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Ages 18 to 60
- •Signing consent form to participate in the study
- •Observing the study conditions and tendency to attend regular follow-up courses
- •Insensitivity of volunteers to the experimental herbal composition
- •Insensitivity or mild sensitivity to mosquito bites
排除标准
- •Documented sensitivity to formulation components
- •susceptibility to mosquito bites
- •active smokers
研究者
相似试验
撤回
4 期
Evaluation of weekly tafenoquine antimalarial prophylaxis in Vietnam People’s Army personnel in South SudaInfection - Other infectious diseasesMalariaACTRN12622000272796Australian Defence Force Malaria and Infectious Disease Institute63
尚未招募
1 期
Characterization and evaluation of the safety and effectiveness of human umbilical cord blood serum alginate hydrogel on patients with 2A degree burns.IRCT20221130056672N3Tehran University of Medical Sciences30
招募中
不适用
Evaluation of the safety, effectiveness and natural care approach of the Jauni phototherapy romper.icterusJaundice10019654NL-OMON56682Erasmus MC, Universitair Medisch Centrum Rotterdam12
进行中（未招募）
1 期
The evaluation of the effectiveness, safety and tolerability of treatment, using a specialized prostate-specific membrane antigen (PSMA) labeled with Lutetium177, in patients with recurrent and/or metastatic adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trialAdenoid cystic carcinomaCTIS2023-504699-73-00arodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy32
进行中（未招募）
1 期
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12